Sep 08 2025 eGenesis Announces IND Clearance for EGEN-2784 in Kidney Transplant and Landmark Patient Updates in Ongoing Expanded Access Study Kidney FDA
Aug 19 2025 eGenesis Appoints Douglas Williams , Ph.D., and Adam Craig, M.D., Ph.D., to its Board of Directors Company
Apr 15 2025 eGenesis and OrganOx Announce U.S. FDA Clearance of IND Application for the Treatment of Patients with Acute-On-Chronic Liver Failure Liver
Feb 07 2025 eGenesis Announces Second Patient Successfully Transplanted with Genetically Engineered Porcine Kidney Kidney
Nov 12 2024 OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for Treatment of Patients with Liver Failure in the Acute Setting Liver Partnerships
Sep 04 2024 eGenesis Raises $191 Million Series D Financing to Advance Lead Program for Kidney Transplant Company
Mar 21 2024 eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient Kidney
Feb 13 2024 eGenesis and PorMedTec Announce Successful Production of Genetically Engineered Porcine Donors in Japan Kidney Company
Jan 19 2024 eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor Liver Partnerships
Oct 25 2023 eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference Company
